Munich, Germany, 9 February 2011 – TOMORROW FOCUS AG has acquired the remaining 49.01 percent of jameda GmbH. The purchase was effective from 3 February 2011. At the same time, Dr Philipp Goos was appointed Managing Director of the company.
jameda GmbH operates the physician rating portal jameda.de. Although the company was only founded in 2007, the portal already handles over a million searches per month and is still growing rapidly. With over 1.5 million visits in January 2011 – an increase of 124 percent on the same month in 2010 – jameda.de is one of the biggest physician rating portals in Germany. It was the only portal to meet 85 percent of the stipulated quality criteria in a survey of ten physician rating portals commissioned by the German Medical Association and the National Association of Statutory Health Insurance Physicians in October 2010. As such, it came out of the survey in first place.
The remaining 49.01 percent of the company’s shares were acquired by Focus Magazin Verlag GmbH in a deal worth EUR 0.85 million including the settlement of shareholder loans. As a result, TOMORROW FOCUS AG now holds 100 percent of the shares in jameda GmbH.
Dr Philipp Goos (34) was appointed simultaneously to the position of Managing Director at jameda GmbH. His role is to take the company forward in collaboration with its founders Barbara Nowak, Michael Nowak, Markus Reif and Jan Richter.
Prior to this appointment, Dr Goos was previously Head of Corporate Development at TOMORROW FOCUS AG, a position he had held since 2008 and in which he was responsible for Strategy and M&A.
Commenting on these latest developments, Stefan Winners, Chief Executive Officer at TOMORROW FOCUS AG, noted that “jameda.de has continuously increased its reach figures ever since it was launched and continues to grow at a rapid pace. Its success is due to the commitment and outstanding work of the company’s founders, led by Michael Nowak and Markus Reif. Together with Dr. Philipp Goos, they make a formidable team – one that can build further on jameda’s current market position and guide the company towards sustained profitability.”